Ticker Details
Nektar Therapeutics Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain.
IPO Date:	May 3, 1994
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$2.06B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.40 | 2.60%
Avg Daily Range (30 D):	$1.80 | 3.74%
Avg Daily Range (90 D):	$1.88 | 3.57%

Institutional Daily Volume
Avg Daily Volume:	.65M
Avg Daily Volume (30 D):	1.23M
Avg Daily Volume (90 D):	.92M

Trade Size
Avg Trade Size (Sh.):	72
Avg Trade Size (Sh.) (30 D):	66
Avg Trade Size (Sh.) (90 D):	64

Institutional Trades
Total Institutional Trades:	9,293
Avg Institutional Trade:	$2.68M
Avg Institutional Trade (30 D):	$2.34M
Avg Institutional Trade (90 D):	$2.19M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.86M
Avg Closing Trade (30 D):	$3.68M
Avg Closing Trade (90 D):	$3.14M
Avg Closing Volume:	17.97K

News

Dec 2, 2025 @ 2:00 PM ADARx Pharmaceuticals Appoints Mary Tagliaferri, M... Source: Dr. Zhen Li

Aug 8, 2025 @ 10:15 PM Why Nektar Therapeutics Stock Popped 6% on Friday Source: Eric Volkman

Aug 9, 2024 @ 2:58 PM Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenue... Source: N/A

May 10, 2024 @ 3:33 PM Nektar's (NKTR) Q1 Earnings and Revenues Surpass E... Source: Zacks Equity Research

Apr 10, 2024 @ 4:29 AM Nektar Therapeutics Sees Something In The Data And... Source: Biotech Beast

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$.55	$-1.87	$-2.95
Diluted EPS	$.55	$-1.87	$-2.95
Revenue	$62.6M	$11.79M	$11.18M
Gross Profit
Net Income / Loss	$-120.74M	$-35.52M	$-41.59M
Operating Income / Loss	$-98.09M	$-31.67M	$-36.23M
Cost of Revenue	$7.98M	$M	$M
Net Cash Flow	$10.92M	$-1.96M	$4.09M
PE Ratio	123.64

Splits
Jun 09, 2025	1:15
Aug 23, 2000	2:1